AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01477-07v1
52/5/1843    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Fritsche, T. R.
Right arrow Articles by Armstrong, E. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fritsche, T. R.
Right arrow Articles by Armstrong, E. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2008, p. 1843-1845, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01477-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Detection of Methyltransferases Conferring High-Level Resistance to Aminoglycosides in Enterobacteriaceae from Europe, North America, and Latin America{triangledown}

Thomas R. Fritsche,1* Mariana Castanheira,1 George H. Miller,2 Ronald N. Jones,1,3 and Eliana S. Armstrong2

JMI Laboratories, North Liberty, Iowa,1 Achaogen, Inc., South San Francisco, California,2 Tufts University School of Medicine, Boston, Massachusetts3

Received 14 November 2007/ Returned for modification 21 December 2007/ Accepted 25 February 2008


   ABSTRACT
Top
 ABSTRACT
TEXT
 REFERENCES
 
The alteration of ribosomal targets by recently described 16S rRNA methyltransferases confers resistance to most aminoglycosides, including arbekacin. Enterobacteriaceae and nonfermentative bacilli acquired through global surveillance programs were screened for the presence of these enzymes on the basis of phenotypes that were resistant to nine tested aminoglycosides. Subsequent molecular studies determined that 20 of 21 (95.2%) methyltransferase-positive isolates consisted of novel species records or geographic occurrences (North America [armA and rmtB], Latin America [rmtD], and Europe [armA]; rmtA, rmtC, and npmA were not detected). The global emergence of high-level aminoglycoside resistance has become a rapidly changing event requiring careful monitoring.


   TEXT
Top
 ABSTRACT
 TEXT
REFERENCES
 
Aminoglycosides continue to play an important role in antimicrobial therapy against both gram-negative and gram-positive pathogens, usually in combination with β-lactam agents. Resistance to the class can be widespread and has primarily been the result of aminoglycoside inactivation through the chemical processes of acetylation, phosphorylation, and/or adenylation, with varying effects depending upon the particular agent (14). Since 2003, methylation of 16S rRNA has emerged as a serious threat to the class through the action of plasmid-mediated methyltransferase enzymes (6, 9-11, 17). These enzymes, which are similar to those found in actinomycetes, confer intrinsic resistance to the aminoglycoside agents they produce (6, 13, 15).

Alteration of the 16S rRNA A site by these enzymes (designated ArmA, RmtA, RmtB, RmtC, RmtD, and NpmA) confers resistance to almost all aminoglycosides, including arbekacin, by limiting the binding of these agents to ribosomal target sites following methylation of specific nucleotides. armA (Enterobacteriaceae, Acinetobacter spp.) and rmtB (Enterobacteriaceae) appear to be the most widespread and have been detected primarily in Asia and Europe (1, 2, 9, 12, 17, 18, 20); armA has also been reported from a clone of Acinetobacter baumannii found in the United States (Pennsylvania) (5). rmtA and rmtC have been reported only from Japan (Pseudomonas aeruginosa and Proteus mirabilis, respectively) and rmtD from Brazil (P. aeruginosa) (7, 8, 15, 18, 19). A sixth plasmid-mediated methyltransferase enzyme, NpmA, was recently obtained from a strain of Escherichia coli recovered from a Japanese patient (16). NpmA is unique in that it produces a broad resistance phenotype to aminoglycosides including apramycin and neomycin, due to methylation of the A1408 position at the A site of 16S rRNA; all other methyltransferases described to date from clinical isolates methylate the G1405 position. The high level of resistance produced by these methyltransferases and their association with mobile genetic elements have become a worrisome development that will require enhanced laboratory capabilities for detection, appropriate infection control practices to limit continued spread, and when detected, reliance on alternative chemotherapeutic agents (6, 10, 11, 17).

While the occurrence of 16S methylation by these gene products appears to be widespread globally, structured prevalence data are urgently needed. We evaluated Enterobacteriaceae family members and nonfermentative bacilli acquired through global surveillance programs for the presence of methyltransferases, based upon patterns of resistance to commonly used aminoglycosides.

Enterobacteriaceae (262 isolates), P. aeruginosa (95 isolates) and Acinetobacter spp. (50 isolates) were selected from recent surveillance collections (from North America, Latin America, and Europe) on the basis of their resistance to combinations of gentamicin, tobramycin, and amikacin and were tested further for susceptibility using the Clinical Laboratory Standards Institute (CLSI) broth microdilution methods against six other aminoglycosides (apramycin, arbekacin, fortimicin, kanamycin, neomycin, and netilmicin) (3, 4). High-level resistance to all aminoglycosides in the panel, except for apramycin and neomycin, has been described as the defining phenotype characteristic for ArmA, RmtA, RmtB, RmtC, and RmtD methyltransferase resistance mechanisms; additionally, resistance to apramycin and neomycin appears to be typical for the NpmA mechanism (6, 16). Strains were selected for further study based on the MIC results from this aminoglycoside screen.

Primers for diagnostic amplification of the armA, rmtA to rmtD, and npmA genes were designed from sequences deposited in the GenBank database or were selected from the literature (Table 1) (15, 19). Primers were designed to have similar annealing temperatures for simultaneous amplification on a single thermocycler program. Templates for PCRs were prepared by suspending a single colony in 100 µl of sterile water. Suspensions were heated to 95°C for 10 min, cooled to room temperature, and centrifuged to pellet the cell debris. The addition of 2 µl of the template supernatant to reaction mixtures containing the appropriate primer sets was used to initiate reactions.


View this table:
[in this window]
[in a new window]

  		TABLE 1. PCR primer sets utilized in the detection of aminoglycoside methyltransferase resistance genes

 
Amplification was performed in an Eppendorf Mastercycler (Eppendorf, Westbury, NY). The PCR method consisted of 25 cycles of denaturation at 94°C for 15 s, annealing at 58°C (45°C for those isolates found to be PCR negative at 58°C) for 30 s, and extension at 72°C for 60 s. This was followed by an additional 10-min extension at 72°C. The entire reaction mixture was loaded onto an E-Gel (Invitrogen, Carlsbad, CA) for rapid gel electrophoresis. Visualization of bands by UV light confirmed the presence of the target methylase gene. A plasmid containing the armA gene (kindly provided by Patrice Courvalin) was used as a positive control for the presence of armA in the collection of clinical isolates. Upon our initial identification of rmtB and rmtD, these PCR products were submitted for DNA sequencing to confirm their identity by comparison to previously reported sequences. These confirmed strains were subsequently employed as positive controls for further screening.

Susceptibility profiling of 407 gram-negative isolates resistant to combinations of gentamicin, tobramycin, and amikacin in the initial screen revealed 19 strains that were subsequently found to be resistant to all 4,6-di-substituted aminoglycosides (Table 2). Two additional strains were selected on the basis of apramycin susceptibility and neomycin resistance, since aph(3')-I is a widespread resistance gene that reduces the potency of neomycin (14). A final strain chosen for further study displayed high-level resistance to all aminoglycosides tested (including apramycin and neomycin) and was found to be positive for aph(3')-I and aac(3)-IV enzymes (data not shown).


View this table:
[in this window]
[in a new window]

  		TABLE 2. Aminoglycoside resistance profiles among studied Enterobacteriaceae isolates and their detected resistance genes

 
Among the 22 isolates selected for further analysis, 21 (5.2% of the initial screen total) isolates were confirmed to carry methyltransferase genes (9 isolates carried armA, 8 carried rmtB, and 4 carried rmtD; Table 2). armA was detected in isolates from Poland (1 isolate of Enterobacter cloacae, 1 of Escherichia coli, 1 of Klebsiella oxytoca, and 3 of Serratia marcescens), France (1 isolate of K. pneumoniae), and the United States (1 isolate each of K. pneumoniae and E. cloacae), whereas rmtB strains were found in the United States (1 isolate of E. coli), Brazil (1 isolate of E. coli and 2 of P. mirabilis), and Mexico (1 isolate of K. pneumoniae and 3 of E. cloacae; Table 3). rmtD was observed in single isolates from Argentina (K. pneumoniae), Brazil (Citrobacter freundii) and Chile (K. pneumoniae and E. cloacae). No isolates were found to carry rmtA, rmtC, or npmA.


View this table:
[in this window]
[in a new window]

  		TABLE 3. Geographic distribution of 22 Enterobacteriaceae isolates with proven or suspected 16S rRNA methyltransferase genes

 
A methyltransferase gene could not be identified in one isolate (Chile [P. mirabilis]) that met the aminoglycoside resistance screening criteria, suggesting the presence of an additional variant enzyme or some other resistance mechanism, and is being investigated further (16). No methyltransferases were found in this collection among the P. aeruginosa or Acinetobacter sp. isolates, although an earlier pilot study identified armA in an Acinetobacter sp. isolate (Venezuela; data not shown).

In summary, the use of rigorous aminoglycoside resistance screening criteria (nine agents) identified 22 isolates with presumptive 16S rRNA methyltransferases; 21 (95.5%) were confirmed positive for recognized resistance genes (armA [40.9%], rmtB [36.4%], or rmtD [18.2%]). While no isolates with rmtA, rmtC, or npmA were detected, these enzymes have been described periodically in isolates originating from Japan; none of the isolates screened originated from Asia. With one exception (the armA-positive K. pneumoniae isolate from France) 20 of 21 (95.2%) isolates represent new geographic (Europe, United States, Latin America) and/or species occurrences, underscoring the rapid global emergence of this resistance mechanism among Enterobacteriaceae (previously recognized in P. aeruginosa and A. baumannii).

The extraordinary level of aminoglycoside resistance produced by methyltransferases and the association of their genes with mobile elements are troubling developments that will require enhanced laboratory capabilities for detection, appropriate infection control practices to limit continued spread, and when detected, reliance on alternative chemotherapeutic agents. Aminoglycosides continue to play a critical role in therapeutics, often for their synergistic codrug effects when paired with agents from other classes. Adjustments of existing treatment algorithms and the development of new aminoglycoside agents that bind to methylated ribosomes are critically needed to help address this latest example of emerging antimicrobial resistance.


   FOOTNOTES
 
* Corresponding author. Mailing address: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 655-3371. E-mail: Thomas-fritsche{at}jmilabs.com Back

{triangledown} Published ahead of print on 17 March 2008. Back


   REFERENCES
Top
 ABSTRACT
 TEXT
 REFERENCES
 

  1. Bogaerts, P., M. Galimand, C. Bauraing, A. Deplano, R. Vanhoof, R. De Mendonca, H. Rodriguez-Villalobos, M. Struelens, and Y. Glupczynski. 2007. Emergence of ArmA and RmtB aminoglycoside resistance 16S rRNA methylases in Belgium. J. Antimicrob. Chemother. 59:459-464.[Abstract/Free Full Text]
  2. Chen, L., Z. L. Chen, J. H. Liu, Z. L. Zeng, J. Y. Ma, and H. X. Jiang. 2007. Emergence of rmtB methylase-producing Escherichia coli and Enterobacter cloacae isolates from pigs in China. J. Antimicrob. Chemother. 59:880-885.[Abstract/Free Full Text]
  3. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
  4. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI/NCCLS M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
  5. Doi, Y., J. M. Adams, K. Yamane, and D. L. Paterson. 2007. Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. Antimicrob. Agents Chemother. 51:4209-4210.[Abstract/Free Full Text]
  6. Doi, Y., and Y. Arakawa. 2007. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis. 45:88-94.[CrossRef][Medline]
  7. Doi, Y., D. de Oliveira Garcia, J. Adams, and D. L. Paterson. 2007. Coproduction of novel 16S rRNA methylase rmtD and metallo-β-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob. Agents Chemother. 51:852-856.[Abstract/Free Full Text]
  8. Doi, Y., A. C. Ghilardi, J. Adams, D. de Oliveira Garcia, and D. L. Paterson. 2007. High prevalence of metallo-β-lactamase and 16S rRNA methylase coproduction among imipenem-resistant Pseudomonas aeruginosa isolates in Brazil. Antimicrob. Agents Chemother. 51:3388-3390.[Abstract/Free Full Text]
  9. Galimand, M., P. Courvalin, and T. Lambert. 2003. Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation. Antimicrob. Agents Chemother. 47:2565-2571.[Abstract/Free Full Text]
  10. Galimand, M., S. Sabtcheva, P. Courvalin, and T. Lambert. 2005. Worldwide disseminated armA aminoglycoside resistance methylase gene is borne by composite transposon Tn1548. Antimicrob. Agents Chemother. 49:2949-2953.[Abstract/Free Full Text]
  11. Gonzalez-Zorn, B., A. Catalan, J. A. Escudero, L. Dominguez, T. Teshager, C. Porrero, and M. A. Moreno. 2005. Genetic basis for dissemination of armA. J. Antimicrob. Chemother. 56:583-585.[Abstract/Free Full Text]
  12. Lee, H., D. Yong, J. H. Yum, K. H. Roh, K. Lee, K. Yamane, Y. Arakawa, and Y. Chong. 2006. Dissemination of 16S rRNA methylase-mediated highly amikacin-resistant isolates of Klebsiella pneumoniae and Acinetobacter baumannii in Korea. Diagn. Microbiol. Infect. Dis. 56:305-312.[CrossRef][Medline]
  13. Liou, G. F., S. Yoshizawa, P. Courvalin, and M. Galimand. 2006. Aminoglycoside resistance by armA-mediated ribosomal 16S methylation in human bacterial pathogens. J. Mol. Biol. 359:358-364.[CrossRef][Medline]
  14. Vakulenko, S. B., and S. Mobashery. 2003. Versatility of aminoglycosides and prospects for their future. Clin. Microbiol. Rev. 16:430-450.[Abstract/Free Full Text]
  15. Wachino, J., K. Yamane, K. Shibayama, H. Kurokawa, N. Shibata, S. Suzuki, Y. Doi, K. Kimura, Y. Ike, and Y. Arakawa. 2006. Novel plasmid-mediated 16S rRNA methylase, RmtC, found in a Proteus mirabilis isolate demonstrating extraordinary high-level resistance against various aminoglycosides. Antimicrob. Agents Chemother. 50:178-184.[Abstract/Free Full Text]
  16. Wachino, J. I., K. Shibayama, H. Kurokawa, K. Kimura, K. Yamane, S. Suzuki, N. Shibata, Y. Ike, and Y. Arakawa. 2007. Plasmid-mediated novel m1A1408 methyltransferase, NpmA, for 16S rRNA found in clinically isolated Escherichia coli resistant to structurally diverse aminoglycosides. Antimicrob. Agents Chemother. 51:4401-4409.[Abstract/Free Full Text]
  17. Yamane, K., J. Wachino, Y. Doi, H. Kurokawa, and Y. Arakawa. 2005. Global spread of multiple aminoglycoside resistance genes. Emerg. Infect. Dis. 11:951-953.[Medline]
  18. Yamane, K., J. Wachino, S. Suzuki, H. Kato, K. Shibayama, K. Kimura, K. Kumiko, I. Satoshi, Y. Ozawa, K. Toshifumi, and Y. Arakawa. 2007. 16S rRNA methylase-producing, Gram-negative pathogens, Japan. Emerg. Infect. Dis. 13:642-646.[Medline]
  19. Yokoyama, K., Y. Doi, K. Yamane, H. Kurokawa, N. Shibata, K. Shibayama, T. Yagi, H. Kato, and Y. Arakawa. 2003. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 362:1888-1893.[CrossRef][Medline]
  20. Yu, Y. S., H. Zhou, Q. Yang, Y. G. Chen, and L. J. Li. 2007. Widespread occurrence of aminoglycoside resistance due to armA methylase in imipenem-resistant Acinetobacter baumannii isolates in China. J. Antimicrob. Chemother. 60:454-455.[Free Full Text]

Antimicrobial Agents and Chemotherapy, May 2008, p. 1843-1845, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01477-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01477-07v1
52/5/1843    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Fritsche, T. R.
Right arrow Articles by Armstrong, E. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fritsche, T. R.
Right arrow Articles by Armstrong, E. S.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS